TrialSpark announces partnership with major pharmaceutical company to jointly acquire and develop clinical-stage novel therapies
NEW YORK, Oct. 4, 2022 /PRNewswire/ -- TrialSpark today announced a new partnership with global pharmaceutical company Sanofi to explore novel methods of bringing new treatments to patients faster and more efficiently. The collaboration will focus on jointly pursuing the acquisition/in-licensing and development of best-in-class, clinical-stage Phase II and Phase III drug candidates in areas of high unmet patient need.